ClinicalTrials.Veeva

Menu
I

IRIS Research and Development | Plantation, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Baricitinib
Secukinumab
HZN-825
Filgotinib
LY3009104
HZN-1116
PF-06823859
Lanraplenib
Fludarabine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 34 total trials

A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).

Enrolling
Sjogren's Syndrome
Drug: HZN-1116
Drug: Placebo

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to seve...

Enrolling
Lupus Erythematosus, Systemic
Drug: Placebo
Drug: Cenerimod

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Placebo
Biological: Risankizumab

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting
Psoriatic Arthritis (PsA)
Biological: Placebo
Biological: Risankizumab

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythema...

Enrolling
Systemic Lupus Erythematosus
Other: Placebo
Drug: Afimetoran

This study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype...

Active, not recruiting
Scleroderma, Systemic
Drug: Placebo
Drug: Avenciguat (BI 685509)

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Active, not recruiting
Rheumatoid Arthritis
Drug: Baricitinib
Drug: TNF Inhibitor

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Enrolling
Rheumatoid Arthritis
Drug: Baricitinib
Drug: TNF Inhibitor

The purpose of the study is to understand how the study medicine PF-06823859 works in people with idiopathic inflammatory myopathies (DM and PM). The...

Enrolling
Myositis
Drug: PF-06823859
Drug: Placebo

The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the...

Active, not recruiting
Rheumatoid Arthritis
Drug: Filgotinib
Drug: Placebo to match filgotinib

This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is...

Enrolling
Granulomatosis With Polyangiitis
Pemphigus Vulgaris
Drug: Fludarabine
Drug: AB-101

This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with gi...

Active, not recruiting
Giant Cell Arteritis (GCA)
Biological: Secukinumab 150 mg
Other: Placebo
Locations recently updated

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling
Systemic Lupus Erythematosus
Drug: Upadacitinib
Drug: Placebo

The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the...

Enrolling
Autoimmunity, Inflammation
Biological: Secukinumab s.c. injection

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderat...

Active, not recruiting
Rheumatoid Arthritis
Procedure: Implant Procedure
Device: Non-active stimulation

Trial sponsors

AbbVie logo
Amgen logo
Novartis logo
Lilly logo
I
A
Boehringer Ingelheim logo
Bristol-Myers Squibb (BMS) logo
Gilead Sciences logo
Idorsia Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems